stockrow
Saturday 7 November 2026
Export URGN’s income statement to Excel — free account
Urogen Pharma
URGN Healthcare Biotechnology
Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024.
- Revenue
- +223.9%
- EPS
- +95.8%
- Free cash flow
- +64.0%
- Total debt
- +57.2%
Quarter to September 2026, against a year earlier
24.81
0.92
−3.58%
Follow URGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.21 | 9.82 | 6.42 | 10.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(135.15) | (56.17) | (19.91) | (29.40) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.61 | 10.26 | 6.76 | 10.30 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.34) | (12.18) | (5.73) | (6.96) | |
EV/FCF |
(16.31) | (12.17) | (5.72) | (6.95) | |
Quick Ratio |
2.83 | 3.20 | 3.89 | 3.34 | |
Current Ratio |
3.40 | 3.80 | 4.69 | 4.01 | |
Net Debt/EBITDA |
11.90 | 505.33 | (2.38) | (0.19) | |
Debt/Assets |
70.60% | 75.88% | 74.71% | 62.70% | |
Debt/Equity |
(1.53) | (1.45) | (1.53) | (1.19) | |
Asset Turnover |
1.10 | 0.82 | 0.56 | 0.45 | |
Operating CF/Net income |
10.40 | 2.30 | 1.92 | 1.45 | |
Capex/Depreciation |
(0.89) | (1.15) | (0.53) | 0.01 | |
Interest Coverage |
1.83 | 0.02 | (4.84) | (7.57) | |
Research and Development Expense of Revenue |
29.17% | 23.93% | 30.61% | 37.83% | |
Selling, General and Administrative Expense of Revenue |
53.04% | 66.85% | 101.03% | 104.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.02% | 7.36% | 9.08% | 8.27% | |
Graham Net Nets |
(0.07) | (0.08) | (0.16) | (0.11) | |
Graham Number |
8.57 | 10.82 | 12.38 | 12.56 | |
Earnings Yield |
(3.25%) | (5.38%) | (15.29%) | (13.66%) | |
Free Cash Flow Yield |
(6.43%) | (8.58%) | (18.40%) | (14.44%) | |
Revenue per Share |
1.76 | 1.44 | 1.02 | 0.79 | |
Operating CF per Share |
(0.30) | (0.66) | (0.90) | (0.80) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.66) | (0.90) | (0.80) | |
Cash per Share |
1.82 | 2.17 | 2.82 | 2.53 | |
Shareholders Equity per Share |
(2.48) | (2.63) | (2.48) | (2.19) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.48) | (2.63) | (2.48) | (2.19) | |
Free Cash Flow |
(15.27) | (33.07) | (45.37) | (38.34) | |
Working Capital |
177.87 | 173.51 | 186.83 | 139.61 | |
Capital Expenditures |
(0.07) | (0.06) | (0.05) | (0.02) | |
Net Current Asset Value |
(145.19) | (149.56) | (140.48) | (119.90) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
68.49 | 54.20 | 37.53 | 26.69 | |
Average Payables |
36.51 | 35.45 | 32.83 | 27.57 | |
Average Inventory |
16.75 | 15.86 | 14.26 | 12.85 | |
Average Assets |
228.46 | 230.65 | 250.65 | 243.08 | |
Average Common Equity |
(120.31) | (112.89) | (85.36) | (57.14) |
Columns are period end dates · fundamentals updated 6 Nov 2026